



**Stefanie Hayoz**

**Contact**

Stefanie Hayoz

## Publications (31)

Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. *Cancer Chemother Pharmacol* 2024; 94:349-360.

Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). *Eur J Cancer* 2024; 201:113588.

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. *J Clin Oncol* 2023; 41:5131-5139.

König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. *ESMO Open* 2023; 8:101595.

Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Breast Cancer Res Treat* 2023; 201:215-225.

Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance J, González-Del-Alba A, Delgado M, Nolè F, Turco F, Mestre R, Ribi K, Cathomas R. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). *J Clin Oncol* 2023; 41:3608-3615.

Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. *Leukemia* 2023; 37:699-701.

Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold D, Putora P, Berthold D, Zihler D, Zengerling F, Dieing A, Mueller A, Schaer C, Biaggi C, Gillessen S, Cathomas R. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. *Lancet Oncol* 2022; 23:1441-1450.

Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner A, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T. Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. *Eur J Cancer* 2022; 177:186-193.

Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. *Blood Adv* 2022; 6:3911-3920.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, Krueger T, Perentes J, Schmid R, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel R, Rothschild S, Hayoz S, Opitz I. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. *J Thorac Cardiovasc Surg* 2022; 164:1587-1602.e5.

Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. *Eur Urol Oncol* 2022; 5:195-202.

Beck M, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti D, Reuter C, Gomez S, Khanfir K, Aebersold D, Ghadjar P, Schär C, Hayoz S, Papachristofilou A, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen D, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller A, Putora P, Pra A. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. *Int J Radiat Oncol Biol Phys* 2022; 113:80-91.

Knauer M, Winkler J, Reinisch M, Reitsamer R, Singer C, Reisenberger K, Hager C, Fansa H, Exner R, Dubsky P, Berclaz G, Leo C, Lam G, Fehr M, Naydina T, Heil J, Egle D, Lelièvre L, Markellou P, Schulz A, Maggi N, Nussbaumer R, Fitzal F, Ostapenko V, Clerc K, Kohlik M, Dedes K, Sarlos D, Muenst S, Ruhstaller T, Maddox C, Seiler S, Zimmermann F, Gruber G, Zwahlen D, Henke G, Tausch C, Hayoz S, Matrai Z, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Maráz R, Gabriel N, Fehr P, Simonson C, Bucher S, Becciolini C, Meyer I, Satler R, Vrieling C, Újhelyi M, Kurzeder C, Weber W. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Breast* 2021; 60:98-110.

Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. *Eur Urol* 2021; 80:306-315.

Moccia A, Rauch D, Vorobiof D, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Raats J, Del Giglio A, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Zucca E. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. *Blood Adv* 2020; 4:5951-5957.

von Holzen U, Függer R, Königsrainer A, Gloor B, Furrer M, Gerard M, Hawle H, Walz M, Alesina P, Schäfer M, Marti W, Kettelhack C, Schmidt S, Hayoz S, Steffen T, Grieder F, Bartsch D, Schnider A, Knoefel W, Piessen G, Ruhstaller T. Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08). *Ann Surg* 2020

Menter T, Hayoz S, Hawle H, Sander B, Mazzucchelli L, Grobholz R, Karjalainen-Lindsberg M, Cathomas G, Banz Y, Cogliatti S, Beiske K, Sundstrom C, Hultdin M, Kimby E, Zucca E, Tzankov A, Dirnhofer S. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. *Br J Haematol* 2020; 189:707-717.

Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. *Radiat Oncol* 2019; 14:166.

Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. *Blood* 2019; 134:353-362.

Henke G, Kurzeder C, Gyr A, Ballardini B, Matrai Z, Gnant M, Fitzal F, Hawle H, Ackerknecht M, Muenst S, Zwahlen D, Ruhstaller T, Gerard M, Hayoz S, Ribl K, Knauer M, Weber W. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. *Trials* 2018; 19:667.

Weber W, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal S, Ruhstaller T, Fehr P, Knauer M, Pioch V, Güth U, Hess T, Tausch C, Hayoz S, Fehr M, Ribl K, Hawle H, Lupatsch J, Matter-Walstra K, Chiesa F, Dedes K, Berclaz G, Lelièvre L, Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. *Ann Surg Oncol* 2018; 25:2632-2640.

von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). *Eur J Cancer* 2017; 89:82-89.

Ghadjar P, Thalmann G, Aebersold D, Wust P, Biaggi Rudolf C, Dal Pra A, Schär C, Papachristofilou A, Putora P, Müller A, Hildebrandt G, Polat B, Gut P, Hölscher T, Stein J, Zwahlen D, Bernhard J, Hayoz S, Swiss Group for Clinical Cancer Research (SAKK). Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. *Radiother Oncol* 2017

Ghadjar P, Kranzbühler H, Najafi Y, Ost P, Azinwi N, Reuter C, Bodis S, Kaouthar K, Budach V, Aebersold D, Thalmann G, Sumila M, Biaggi-Rudolf C, Stalder L, Hayoz S, Genitsch V, Zwahlen D, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller A, Putora P, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. *BJU Int* 2017; 120:E45-E51.

Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). *Prostate* 2016; 76:1519-1527.

Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. *J Pain Symptom Manage* 2014; 48:1160-7.

Rothermundt C, Cathomas R, Rüschoff J, Schiess R, Endt K, Lui L, Pollak M, Bärtschi D, Strebel R, Winterhalder R, Templeton A, Hayoz S, Gillessen Sommer S. Metformin in chemotherapy-naïve castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). *Eur Urol* 2014; 66:468-74.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)